Epidemiology of DYT1 dystonia
Estimating prevalence via genetic ascertainment
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received June 4, 2019
- Accepted in final form August 2, 2019
- First Published September 13, 2019.
Author Disclosures
- Joseph Park, AB,
- Scott M. Damrauer, MD,
- Aris Baras, MD, MBA,
- Jeffrey G. Reid, PhD,
- John D. Overton, PhD and
- Pedro Gonzalez-Alegre, MD, PhD
- Joseph Park, AB,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
National Human Genome Research Institute (NHGRI) of the National Institutes of Health, Award Number F30HG010442, 2019- 2022
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Scott M. Damrauer, MD,
NONE
NONE
NONE
NONE
(1) Novel targets for therapeutic manipulation to treat HDL-C, triglycerides and coronary disease and (2) novel targets for therapeutic manipulation to treat abdominal aortic aneurysms
NONE
NONE
(1) Spouse consulting for Rhythm Pharmaceuticals; (2) Spouse consulting for Reata
NONE
NONE
NONE
(1) RenalytixAI, (2) CytoVas, LLC
(1) U.S. Department of Veterans Affairs, Clinical Science Research and Development, IK2-CX00178-01, PI, 2018-current, (2) National Heart Lung Blood Institute, 1RO1HL138306-01A1, co-investigator, 2018-current; (3) U.S. Department of Veterans Affairs, Basic Science Research and Development, BX- 003362-62, co-investigator, 2017-current.
(1) Vanderbilt University (2) Partners Healthcare
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Aris Baras, MD, MBA,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Jeffrey G. Reid, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
Regeneron Pharmaceuticals, VP Genome Informatics, 6
NONE
NONE
NONE
NONE
Regeneron Pharmaceuticals
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Regeneron Pharmaceuticals
NONE
- John D. Overton, PhD and
NONE
NONE
NONE
NONE
NONE
NONE
Regeneron Genetics Center, Vice President and Head of Sequencing and Lab Operations, 6 years
NONE
NONE
NONE
NONE
Regeneron Genetics Center/Regeneron Pharmaceuticals
NONE
NONE
NONE
Regeneron Pharmaceuticals
NONE
NONE
NONE
NONE
NONE
- Pedro Gonzalez-Alegre, MD, PhD
NONE
NONE
- American Academy of Neurology: honoraria as a speaker in Annual Meeting 2017 - Movement Disorders Society (Pan American Section): honoraria as a speaker in School for Young Neurologists 2017
Academic Editor, PLoS One
Patent on Allele-Specific Silencing for disease genes. Based on RNA interference. Licensed by the University of Iowa to Spark Therapeutics
NONE
NONE
- Consulting for Spark Therapeutics (contract pending execution) - Consulting for SAGE Therapeutics (contract pending execution)
NONE
NONE
NONE
NONE
I received research grants from the US Department of Defense and the NIH/NINDS unrelated to this work.
NONE
Research Grant for the Dystonia Medical Research Foundation Research Grant from the Clinical Consortium for X-linked Dystonia Parkinsonism
NONE
Licensing fees from Spark Therapeutics for
NONE
NONE
NONE
NONE
- From the Department of Medicine (J.P.), University of Pennsylvania, Philadelphia; Department of Surgery (S.M.D.), Perelman School of Medicine, University of Pennsylvania, Philadelphia; Regeneron Genetics Center (A.B., J.G.R., J.D.O.), Tarrytown, NY; and Department of Neurology (P.G.-A.), Perelman School of Medicine, University of Pennsylvania, Philadelphia.
- Correspondence
Dr. Gonzalez-Alegre pedro.gonzalez-alegre{at}uphs.upenn.edu
Article usage
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Hastening the Diagnosis of Amyotrophic Lateral Sclerosis
Dr. Brian Callaghan and Dr. Kellen Quigg
► Watch
Related Articles
- No related articles found.
Topics Discussed
Alert Me
Recommended articles
-
Articles
The DYT1 phenotype and guidelines for diagnostic testingS.B. Bressman, C. Sabatti, D. Raymond et al.Neurology, May 09, 2000 -
Clinical/Scientific Notes
SUSCEPTIBILITY TO DYT1 DYSTONIA IN EUROPEAN PATIENTS IS MODIFIED BY THE D216H POLYMORPHISMC. Kamm, H. Fischer, B. Garavaglia et al.Neurology, June 02, 2008 -
Articles
Mutations in DYT1Extension of the phenotypic and mutational spectrumK. Kabakci, K. Hedrich, J. C. Leung et al.Neurology, February 09, 2004 -
Editorials
To test or not to test?That is the question (with a twist)David G. Lichter, Anthony E. Lang et al.Neurology, May 09, 2000